ALX Oncology Holdings Inc. ALXO
1.31
(0.05)
(3.68%)
as of 25 Sep
- Market cap
- $187.4M
- P/E
- 0.0×
Follow ALXO
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| ROE | (80.65%) | (74.17%) | (145.70%) | (118.95%) |
+8 more TTM periods Free account |
| ROA | (63.16%) | (59.40%) | (98.34%) | (80.47%) | |
| ROIC | (673.30%) | (291.68%) | 0.00% | 0.00% | |
| Return on Tangible Assets | (62.78%) | (70.29%) | (371.50%) | (269.05%) | |
| Average Days of Receivables | — | — | — | — | |
| Free Cash Flow per Share | (0.52) | (0.75) | (1.57) | (1.82) | |
| Free Cash Flow | (70.91) | (78.33) | (84.35) | (97.43) | |
| Capital Expenditures | (0.13) | (0.20) | (0.21) | (0.22) | |
| Other line items | |||||
| Cash ROIC | (24.91%) | (26.03%) | (104.50%) | (84.14%) | |
| Accounts Payable Turnover | 0.00 | 0.00 | 0.00 | 0.00 | |
| Average Days of Payables | 0.00 | 0.00 | 0.00 | 0.00 | |
| Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | |
| Research and Development Expense of Revenue | 0.00% | 0.00% | 0.00% | 0.00% | |
| Selling, General and Administrative Expense of Revenue | 0.00% | 0.00% | 0.00% | 0.00% | |
| Share Based Compensation of Revenue | 0.00% | 0.00% | 0.00% | 0.00% | |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating CF/Net income | 0.88 | 0.88 | 0.83 | 0.90 | |
| Depreciation/Fixed assets | (0.77) | 0.01 | (0.21) | (0.55) | |
| Capex/Depreciation | 1.01 | (18.36) | 0.83 | 0.30 | |
| Revenue per Share | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating CF per Share | (0.52) | (0.75) | (1.57) | (1.81) | |
| Capex per Share | 0.00 | 0.00 | 0.00 | 0.00 | |
| Capex to Sales | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates